Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacol Drug Dev ; 7(3): 263-276, 2018 03.
Article in English | MEDLINE | ID: mdl-28783871

ABSTRACT

Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease. This randomized, double-blind, placebo-controlled, positive-controlled, parallel-group thorough QT study characterized the effects of ozanimod on cardiac repolarization in healthy subjects. Eligible subjects were randomized to 1 of 2 groups: ozanimod (escalated from 0.25 to 2 mg over 14 days) or placebo (for 14 days). A single dose of moxifloxacin 400 mg or placebo was administered on days 2 and 17. The primary end point was the time-matched, placebo-corrected, baseline-adjusted mean QTcF (ΔΔQTcF). A total of 113/124 (91.1%) subjects completed the study. The upper limits of the 2-sided 90% confidence intervals for ΔΔQTcF for both ozanimod 1 and 2 mg were below the 10-millisecond regulatory threshold. No QTcF >480 milliseconds or postdose change in QTcF of >60 milliseconds was observed. There was no evidence of a positive relationship between concentrations of ozanimod and its active metabolites and ΔΔQTcF. Although ozanimod blunted the observed diurnal increase in heart rate, excursions below predose heart rates were no greater than with placebo. Results demonstrate that ozanimod does not prolong the QTc interval or cause clinically significant bradycardia, supporting ozanimod's evolving favorable cardiac safety profile.


Subject(s)
Electrocardiography/drug effects , Heart Rate/drug effects , Indans/pharmacology , Oxadiazoles/pharmacology , Receptors, Lysosphingolipid/physiology , Adult , Double-Blind Method , Electrocardiography/methods , Female , Heart Rate/physiology , Humans , Indans/adverse effects , Male , Oxadiazoles/adverse effects
2.
J Clin Pharmacol ; 57(8): 988-996, 2017 08.
Article in English | MEDLINE | ID: mdl-28398597

ABSTRACT

The sphingosine-1-phosphate 1 receptor (S1P1R ) is expressed by lymphocytes, dendritic cells, and vascular endothelial cells and plays a role in the regulation of chronic inflammation and lymphocyte egress from peripheral lymphoid organs. Ozanimod is an oral selective modulator of S1P1R and S1P5R receptors in clinical development for the treatment of chronic immune-mediated, inflammatory diseases. This first-in-human study characterized the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ozanimod in 88 healthy volunteers using a range of single and multiple doses (7 and 28 days) and a dose-escalation regimen. Ozanimod was generally well tolerated up to a maximum single dose of 3 mg and multiple doses of 2 mg/d, with no severe adverse events (AEs) and no dose-limiting toxicities. The most common ozanimod-related AEs included headache, somnolence, dizziness, nausea, and fatigue. Ozanimod exhibited linear PK, high steady-state volume of distribution (73-101 L/kg), moderate oral clearance (204-227 L/h), and an elimination half-life of approximately 17 to 21 hours. Ozanimod produced a robust dose-dependent reduction in total peripheral lymphocytes, with a median decrease of 65% to 68% observed after 28 days of dosing at 1 and 1.5 mg/d, respectively. Ozanimod selectivity affected lymphocyte subtypes, causing marked decreases in cells expressing CCR7 and variable decreases in subsets lacking CCR7. A dose-dependent negative chronotropic effect was observed following the first dose, with the dose-escalation regimen attenuating the first-dose negative chronotropic effect. Ozanimod safety, PK, and PD properties support the once-daily regimens under clinical investigation.


Subject(s)
Indans , Oxadiazoles , Adult , Double-Blind Method , Fasting/metabolism , Female , Healthy Volunteers , Humans , Indans/adverse effects , Indans/blood , Indans/pharmacokinetics , Indans/pharmacology , Lymphocyte Count , Lymphocytes/drug effects , Male , Middle Aged , Oxadiazoles/adverse effects , Oxadiazoles/blood , Oxadiazoles/pharmacokinetics , Oxadiazoles/pharmacology , Receptors, Lysosphingolipid/metabolism , Young Adult
3.
Int J Cancer ; 124(6): 1312-21, 2009 Mar 15.
Article in English | MEDLINE | ID: mdl-19072981

ABSTRACT

The biology of the normal colonic mucosa suggests that colon cancer originates from normal colon stem cells. CD44 cancer stem cells have been identified in breast and prostate cancer, and we therefore examined whether CD44 similarly identified colon cancer stem cells. Initial assays found CD44(hi) colon tumor cells to have enhanced soft agar colony-forming ability. Subsequently, CD44(hi) cells isolated from 4 primary colon adenocarcinoma xenografts were found to be highly tumorigenic in immune deficient mice. CD44(hi) cells consistently formed tumors with 1,000 cells, and in multiple experiments, as few as 10 and 100 CD44(hi) cells formed tumors in 7/10 and 21/28 mice, respectively. In contrast, CD44(-) colon tumor cells were either nontumorigenic or 10-50-fold less tumorigenic. CD44(hi) cells could be serially passaged up to 4 times in vivo, suggesting self-renewal capacity, and formed tumors that recapitulated the heterogeneity of the original patient tumor. CD44(hi) cells were significantly enriched for nuclear activated beta-catenin, a key element in normal stem/progenitor cells and in early colon tumor progression. Bromodeoxyuridine (BrdU) labeling studies indicated that CD44(hi) cells divide slowly relative to the CD44(-) cells, suggesting their tumorigenicity is not simply due to faster proliferation. Aldehyde dehydrogenase (ALDH) sort further increased the tumorigenicity of CD44(hi) cells from 2/2 patient tumors, but CD133 tumor cells in our hands did not have increased tumorigenicity. Our observations indicate that CD44 is a marker of stem-like cells in colon cancer, and support the use of additional markers to further purify colon cancer stem cells.


Subject(s)
Colonic Neoplasms/pathology , Intestinal Mucosa/pathology , Stem Cells/pathology , Adenocarcinoma/pathology , Animals , Antigens, CD/analysis , Cell Line, Tumor , Colonic Neoplasms/epidemiology , Colonic Neoplasms/mortality , Developed Countries , Flow Cytometry , Humans , Hyaluronan Receptors/analysis , Incidence , Mice , Mice, SCID , Mice, Transgenic , Stem Cells/cytology , Transplantation, Heterologous
4.
Am J Transplant ; 5(3): 443-53, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15707398

ABSTRACT

Current success in organ transplantation is dependent upon the use of calcineurin-inhibitor-based immunosuppressive regimens. Unfortunately, current immunotherapy targets molecules with ubiquitous expression resulting in devastating non-immune side effects. T-cell costimulation has been identified as a new potential immunosuppressive target. The best characterized pathway includes CD28, its homologue CTLA4 and their ligands CD80 and CD86. While an immunoglobulin fusion protein construct of CTLA4 suppressed rejection in rodents, it lacked efficacy in primate transplant models. In an attempt to increase the biologic potency of the parent molecule a novel, modified version of CTLA4-Ig, LEA29Y (belatacept), was constructed. Two amino acid substitutions (L104E and A29Y) gave rise to slower dissociation rates for both CD86 and CD80. The increased avidity resulted in a 10-fold increase in potency in vitro and significant prolongation of renal allograft survival in a pre-clinical primate model. The use of immunoselective biologics may provide effective maintenance immunosuppression while avoiding the collateral toxicities associated with conventional immunsuppressants.


Subject(s)
Antigens, Differentiation/pharmacology , Immunoconjugates/immunology , Abatacept , Animals , Antigens, CD/immunology , Antigens, Differentiation/genetics , Antigens, Differentiation/immunology , B7-2 Antigen , CD28 Antigens/immunology , CHO Cells , CTLA-4 Antigen , Cell Proliferation/drug effects , Cricetinae , Cricetulus , Humans , Immunoconjugates/genetics , Kinetics , Membrane Glycoproteins/immunology , Protein Engineering , T-Lymphocytes/drug effects
5.
Eur J Immunol ; 33(8): 2074-82, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12884280

ABSTRACT

We used 5-(and 6-) carboxyfluorescein diacetate succinimidyl ester labeled TCR-transgenic CD4(+) T cells to investigate the contribution of B7 costimulation to T cell activation and clonal expansion. B7 costimulation was blocked with the fusion protein cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)-Ig, which prevents the interaction of B7 with its receptor CD28 on T cells. CTLA4-Ig had different effects depending on the density of antigen (Ag)/MHC ligands available by T cells. In the presence of CTLA4-Ig, tenfold higher concentrations of Ag were required for T cells to undergo cell division in vitro. At high Ag concentrations, T cell division occurred at comparable rates whether in the presence or absence of CTLA4-Ig; however, T cell survival and clonal expansion were strongly inhibited. Addition of IL-2 restored T cell survival but not responsiveness to low doses of Ag. In vivo, B7 costimulation was similarly required for the survival of Ag-specific T cells but not for cell division in response to high amounts of Ag. Thus, B7 costimulation regulates CD4(+) T cell responses by promoting cell division in the presence of limiting amounts of Ag, and by protecting T cells from the onset of apoptosis.


Subject(s)
Antigens, CD/metabolism , B7-1 Antigen/metabolism , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Membrane Glycoproteins/metabolism , Abatacept , Adoptive Transfer , Animals , Antigens/administration & dosage , B7-2 Antigen , CD4-Positive T-Lymphocytes/drug effects , Cell Division/drug effects , Cell Survival/drug effects , Cytochrome c Group/immunology , Immunoconjugates/pharmacology , In Vitro Techniques , Lymphocyte Activation/drug effects , Mice , Mice, Transgenic , Peptide Fragments/immunology , Receptors, Antigen, T-Cell/genetics , Recombinant Fusion Proteins/pharmacology , Thymidine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL